SynCardia COO to Spotlight Women's Heart Failure Access at Arizona Tech Week

Event summary

  • SynCardia COO Matt Schuster will deliver a keynote at Venture Café Phoenix on April 9, 2026, during Arizona Tech Week.
  • The keynote will focus on expanding access to artificial heart technology, particularly for women with advanced heart failure.
  • SynCardia’s Total Artificial Heart has been implanted over 2,100 times in 27 countries.
  • The presentation will highlight recent clinical experience at the University of California, San Francisco, led by Dr. Amy Fiedler.

The big picture

SynCardia’s focus on expanding access to its artificial heart technology, particularly for women, highlights a strategic shift towards addressing healthcare disparities and potentially tapping into a larger patient pool. This initiative comes as the mechanical circulatory support market faces increasing competition and scrutiny regarding long-term outcomes and cost-effectiveness. The company’s reliance on key clinical partners underscores the importance of ongoing clinical validation for maintaining market leadership.

What we're watching

Market Expansion
The focus on women with advanced heart failure suggests SynCardia is targeting a previously underserved market segment, but success will depend on demonstrating efficacy and addressing potential physiological differences in treatment.
Regulatory Landscape
The development of 'next generation, fully implantable' systems will likely require further FDA approvals, potentially delaying market entry and increasing development costs.
Clinical Adoption
Continued reliance on leading transplant centers like UCSF indicates SynCardia's adoption is still concentrated; broader clinical acceptance will be crucial for sustained growth.

Related topics

Medical Devices